QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia
January 29, 2026 10:46 ET | Source: Quetzal Therapeutics CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company focused
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company specializing in
Quetzal Therapeutics Appoints Todd Smith as Board Member
Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.
Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer
September 16, 2025 12:10 ET | Source: Quetzal Therapeutics CHICAGO, Sept. 16, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company focused
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.